Benzinga
Benzinga
Benzinga
sábado, septiembre 12

Corbus Pharmaceuticals Holdings Inc

CRBPNASDAQ
Trade with Public
Trade with Public
$8.12
-0.12-1.46%
al cierre: Sep 11, 5:00 PM EST
$10.44
2.3228.57%
After hour: 7:59 PM EST
PRO
¿Por qué se mueve?:Corbus Pharmaceuticals Holdings shares are trading higher after the company...
Panorámica generalNoticiasPrevisión de beneficiosEventosPrecios objetivoFinanzasSentimientoPropiedadCompararOpcionesInforme de acciones

Corbus Pharmaceuticals Financials

Corbus Pharmaceuticals (CRBP) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Corbus Pharmaceuticals Q2 EPS $(1.81) Misses $(1.26) Estimate

Corbus Pharmaceuticals (NASDAQ:CRBP) reported quarterly losses of $(1.81) per share which missed the analyst consensus estimate of $(1.26) by 43.65 percent. This is a 25.69 percent decrease over losses of $(1.44) per
Benzinga Newsdesk

PRO
Corbus Pharmaceuticals Q1 EPS $(1.23) Misses $(1.22) Estimate

Corbus Pharmaceuticals (NASDAQ:CRBP) reported quarterly losses of $(1.23) per share which missed the analyst consensus estimate of $(1.22) by 0.82 percent. This is a 11.51 percent increase over losses of $(1.39) per
Benzinga Newsdesk

Corbus Pharmaceuticals Q4 Earnings Summary & Key Takeaways

Benzinga Insights

PRO
Corbus Pharmaceuticals Q4 EPS $(1.25) Beats $(1.38) Estimate

Corbus Pharmaceuticals (NASDAQ:CRBP) reported quarterly losses of $(1.25) per share which beat the analyst consensus estimate of $(1.38) by 9.42 percent. This is a 60.26 percent decrease over losses of $(0.78) per share
Benzinga Newsdesk

PRO
Corbus Pharmaceuticals Q3 EPS $(1.90) Misses $(1.72) Estimate

Corbus Pharmaceuticals (NASDAQ:CRBP) reported quarterly losses of $(1.90) per share which missed the analyst consensus estimate of $(1.72) by 10.72 percent. This is a 65.22 percent decrease over losses of $(1.15) per
Benzinga Newsdesk

PRO
Corbus Pharmaceuticals Q2 EPS $(1.44) Beats $(1.52) Estimate

Corbus Pharmaceuticals (NASDAQ:CRBP) reported quarterly losses of $(1.44) per share which beat the analyst consensus estimate of $(1.52) by 5.39 percent. This is a 60 percent decrease over losses of $(0.90) per share
Benzinga Newsdesk

Datos y APIs: APIs de Benzinga · API de noticias de acciones · API de calificaciones de analistas · API de logotipos de empresas

Benzinga

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

© 2026 Benzinga | All Rights Reserved